Source-grounded facts extracted from Viatris Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Viatris Inc incurred senior notes of €650,000,000 with Public holders at 4.250% per annum maturing June 17, 2033.
“On June 17, 2026, Viatris Inc. ("Viatris" or the "Company") completed a public offering of €650,000,000 aggregate principal amount of its 4.250% Senior Notes due 2033 (the "Notes").”
Viatris Inc entered into Indenture with The Bank of New York Mellon, as trustee valued at €650,000,000 (effective 2026-06-17).
“The Notes were issued pursuant to an Indenture (the "Base Indenture"), dated June 17, 2026, among the Company, the Guarantors and The Bank of New York Mellon, as trustee (the "Trustee"), as supplemented by the First Supplemental Indenture (the "Supplemental Indenture" and, together with the Base Indenture, the "Indenture"), dated June 17, 2026, among the Company, the Guarantors and the Trustee (which includes the form of Notes as an exhibit).”
Viatris Inc shareholders approved Ratification of the selection of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-15 meeting.
“December 31, 2026: For Against Abstain Broker Non-Votes 969,259,214 27,657,863 1,101,477 N/A This proposal was approved. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto”
Viatris Inc shareholders approved Approval, on a non-binding advisory basis, of the 2025 compensation of the named executive officers at the 2026-05-15 meeting.
“Don Cornwell 849,532,867 24,182,514 1,841,533 122,461,640 Frank D’Amelio 867,382,258 7,361,498 813,158 122,461,640 JoEllen Lyons Dillon 798,545,833 59,938,622 17,072,459 122,461,640 Elisha Finney 871,844,773 2,902,953 809,188 122,461,640 Leo Groothuis 854,806,833 19,923,045 827,036 122,461,640 Melina Higgins 870,698,982 4,042,667 815,265 122,461,640 James M.”
Viatris Inc shareholders approved Election of thirteen director nominees at the 2026-05-15 meeting.
“Each director nominee was elected to hold office until the 2027 annual meeting of shareholders.”
Viatris Inc updated its first-quarter 2026 guidance (reaffirmed).
“On May 7, 2026 , Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended March 31, 2026.”
Paul Campbell was appointed as interim Chief Financial Officer at Viatris Inc.
“On May 4, 2026, the Board of Directors of the Company (the “Board”) appointed Paul Campbell, Viatris’ current Chief Accounting Officer and Corporate Controller, to also serve as interim Chief Financial Officer of the Company, effective May 8, 2026, until a permanent Chief Financial Officer is appointed by the Board.”
Theodora Mistras resigned as Chief Financial Officer at Viatris Inc.
“On May 1, 2026, Theodora (“Doretta”) Mistras informed Viatris Inc. (the “Company”) that she would voluntarily cease to serve as Chief Financial Officer to pursue another professional opportunity.”
Viatris Inc announced a restructuring with charges of between $700 million and $850 million affecting enterprise-wide (up to approximately 10%).
“For the committed restructuring activities, the Company expects to incur total pre-tax charges ranging between $700 million and $850 million.”
Viatris Inc: Amended Section 2.16(b) to specify timely notice of proxy access nomination when the annual meeting date deviates from the first anniversary of the prior year's meeting (effective 2025-10-24).
“On October 24, 2025, the Board of Directors (the “Board”) of Viatris Inc. (“Viatris” or the “Company”) approved the Amended and Restated Bylaws of Viatris Inc. (the “Amended and Restated Bylaws”), which became effective the same date. The Amended and Restated Bylaws amended Section 2.16(b) to specify timely notice of the Notice of Proxy Access Nomination in the event the date of the annual meeting is more than 30 days before or more than 60 days after the first anniversary of the preceding year’s annual meeting.”
Harry Korman departed as Director at Viatris Inc.
“Rajiv Malik and Harry Korman each notified the Company of his intention to not stand for re-election at the 2025 Annual Meeting and to retire as a member of the Board at the end of his current term”
Rajiv Malik departed as Director at Viatris Inc.
“Rajiv Malik and Harry Korman each notified the Company of his intention to not stand for re-election at the 2025 Annual Meeting and to retire as a member of the Board at the end of his current term”
Viatris Inc completed a disposition involving Cooper Consumer Health SAS and certain of its affiliates for up to €1,950.0 million in cash (closed 2024-07-03).
“On July 3, 2024, Viatris Inc., a Delaware corporation (“ Viatris ” or the “ Company ”), closed the previously announced transaction with Cooper Consumer Health SAS, a French corporation (“ Cooper Consumer Health ”), involving the divestiture by Viatris of substantially all of Viatris’ over-the-counter products business (the “ Business ”) and related assets and liabilities (the “ Transaction ”), to Cooper Consumer Health and certain of its affiliates (collectively, the “ Buyer Parties ”), in exchange for consideration from the Buyer Parties of up to €1,950.0 million in cash on a cash-free, debt-free basis, consisting of (a) €1,850.0 million in cash consideration at closing, subject to certain adjustments as set forth in the Transaction Agreement (defined below), including for net indebtedness and net working capital, and (b) up to €100.0 million in contingent additional cash consideration, which shall be payable by the Buyer Parties to Viatris following closing if the shareholders of th”
Rogério Vivaldi Coelho was appointed as Director at Viatris Inc.
“On June 3, 2024, the Board of Directors (the “Board”) of Viatris Inc. (the “Company”) increased the number of directors on the Board from 11 to 12 and appointed Rogério Vivaldi Coelho, M.D., M.B.A. as an independent (as defined in the applicable NASDAQ listing rules) member of the Board with a term of office expiring at the Company’s 2024 annual meeting of shareholders and appointed him to the recently reestablished Science and Technology Committee of the Board, each appointment effective June 3, 2024.”
Viatris Inc reported the first quarter of 2024 results: revenue $3.66 Billion, net income $113.9 Million, EPS $0.09. Guidance reaffirmed.
“Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges • Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted EPS of $0.67”
Viatris Inc reported fourth quarter and full year 2023 results: revenue $15.4 Billion, net income $54.7 Million.
“Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance • Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow[1] • Reports 2023 Total Revenues of $15.4 Billion, U.S. GAAP Net Earnings of $54.7 Million, Adjusted EBITDA of $5.1 Billion, U.S. GAAP Net Cash Provided by Operating Activities of $2.8 Billion and Free Cash Flow of $2.4 Billion”
Viatris Inc entered into Transaction Agreement with Cooper Consumer Health SAS valued at purchase of substantially all of Viatris’ over-the-counter products business (effective 2024-01-29).
“on January 29, 2024, Viatris, Viatris Italia S.r.l., a wholly-owned subsidiary of Viatris, Ipex AB, a wholly-owned subsidiary of Viatris, and the Buyer Parties entered into the Transaction Agreement.”
Viatris Inc: Shareholders approved amendment to Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.
“Proposal No. 5 – Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation: For Against Abstain Broker Non-Votes 712,407,131 165,367,429 3,861,922 129,069,367 This proposal was approved.”
Viatris Inc: Shareholders approved amendment to Certificate of Incorporation to add a federal forum selection provision.
“Proposal No. 4 – Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to add a federal forum selection provision: For Against Abstain Broker Non-Votes 775,943,332 101,876,413 3,774,593 129,111,511 This proposal was approved.”
Viatris Inc: Board approved Amended and Restated Bylaws, effective after 2023 annual meeting, updating universal proxy rules and Delaware law procedures (effective 2023-12-14).
“On December 14, 2023, the Board of Directors (the “Board”) of Viatris Inc. (“Viatris” or the “Company”) approved the Amended and Restated Bylaws of Viatris Inc. (the “Amended and Restated Bylaws”), which became effective immediately after the 2023 annual meeting of shareholders (the “2023 Annual Meeting”).”
Viatris Inc shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation at the 2023-12-15 meeting.
“Proposal No. 5 – Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation: For Against Abstain Broker Non-Votes 712,407,131 165,367,429 3,861,922 129,069,367”
Viatris Inc shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to add a federal forum selection provision at the 2023-12-15 meeting.
“Proposal No. 4 – Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to add a federal forum selection provision: For Against Abstain Broker Non-Votes 775,943,332 101,876,413 3,774,593 129,111,511”
Viatris Inc shareholders approved Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-12-15 meeting.
“Proposal No. 3 – Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstain Broker Non-Votes 951,005,898 55,389,016 4,310,936 N/A”
Viatris Inc shareholders approved Approval, on a non-binding advisory basis, of the 2022 compensation of the named executive officers of the Company at the 2023-12-15 meeting.
“Proposal No. 2 – Approval, on a non-binding advisory basis, of the 2022 compensation of the named executive officers of the Company: For Against Abstain Broker Non-Votes 751,056,625 125,615,255 4,962,588 129,071,382”
Viatris Inc shareholders approved Election of eleven director nominees at the 2023-12-15 meeting.
“Proposal No. 1 - Election of the following eleven director nominees, each to hold office until the 2024 annual meeting of shareholders: Nominee For Against Abstain Broker Non-Votes W. Don Cornwell 866,064,217 12,641,904 2,928,374 129,071,354 JoEllen Lyons Dillon 737,415,797 141,442,673 2,776,030 129,071,350 Elisha W. Finney 858,566,340 20,133,375 2,894,785 129,111,349 Leo Groothuis 872,997,150 5,758,236 2,876,110 129,074,353 Melina Higgins 823,591,802 55,258,023 2,784,503 129,071,520 James M. Kilts 822,629,367 56,144,991 2,860,131 129,071,359 Harry A. Korman 773,082,826 105,601,971 2,849,699 129,171,353 Rajiv Malik 791,020,816 87,750,089 2,863,590 129,071,354 Richard A. Mark, C.P.A. 867,190,829 11,613,601 2,829,062 129,072,357 Mark W. Parrish 833,335,130 45,420,155 2,879,204 129,071,360 Scott A. Smith 871,110,883 7,619,635 2,903,975 129,071,356”
Theodora (Doretta) Mistras was appointed as Chief Financial Officer at Viatris Inc.
“On December 14, 2023, the Company appointed Theodora (Doretta) Mistras to serve as the Chief Financial Officer of the Company, effective as of March 1, 2024”
Sanjeev Narula departed as Chief Financial Officer at Viatris Inc.
“On December 14, 2023, Viatris Inc. (the “Company”) determined that Sanjeev Narula, Chief Financial Officer, would transition from his role with the Company and cease to serve as Chief Financial Officer effective as of March 1, 2024.”
Viatris Inc updated its the third quarter 2023 guidance (reaffirmed).
“On November 7, 2023, Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended September 30, 2023.”
Anthony Mauro departed as President, Developed Markets at Viatris Inc.
“On October 20, 2023, the Company informed Anthony Mauro, President, Developed Markets, that he will depart from the Company effective as of April 1, 2024 as a result of an elimination of his position in connection with a realignment of the Company’s commercial function.”
Rajiv Malik departed as President at Viatris Inc.
“Rajiv Malik, President, informed Viatris Inc. (the “Company”) of his intention to retire from his executive role with the Company effective as of April 1, 2024.”
Viatris Inc entered into Transaction Agreement with Cooper Consumer Health SAS valued at up to €1,950.0 million (effective 2023-10-01).
“On October 1,2023, Viatris Inc., a Delaware corporation (“ Viatris ” or the “ Company ”) entered into an agreement with Cooper Consumer Health SAS, a French corporation (“ Buyer Parent ”) pursuant to which Buyer Parent made a binding offer (“ the Offer ”), by irrevocably granting Viatris an option (the “ Option ”), to require the Buyer Parent and certain of its affiliates (collectively, the “ Buyer Parties ”) to purchase and assume, as applicable, substantially all of Viatris’ over-the-counter products business (the “ Business ”) and related assets and liabilities, on the terms and subject to the conditions of a negotiated form of Transaction Agreement described below (such form, the “ Transaction Agreement ” and such potential transaction, the “ Transaction ”).”
Viatris Inc reported second quarter 2023 results: revenue $3.92 Billion, net income $264 Million. Guidance reaffirmed.
“Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] • Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $515 Million; and Free Cash Flow of $447 Million for the Quarter”
Leo Groothuis was appointed as Independent Director at Viatris Inc.
“On May 19, 2023, the Board appointed Leo Groothuis as an independent (as defined in the applicable NASDAQ listing rules) member of the Board, effective immediately.”
Robert J. Coury changed role as Executive Chairman at Viatris Inc.
“As a result of Mr. Coury’s agreement to serve in this advisory role, the independent members of the Board and Mr. Coury agreed that Mr. Coury will not stand for re-election at the 2023 Annual Meeting and will cease to be a director and to serve as an officer and employee of the Company effective as of the conclusion of the 2023 Annual Meeting.”
Viatris Inc updated its 2023 guidance (initiated).
“Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance”
Viatris Inc reported the period ended December 31, 2022 results: revenue $16,263.
“Total Revenues $16,200 - $16,700 $(86) $— $16,100 - $16,600 $16,263”
Michael Goettler departed as Chief Executive Officer at Viatris Inc.
“Effective as of April 1, 2023, Michael Goettler, the Company’s current Chief Executive Officer, will cease to serve in that role and will cease to serve on the Board.”
Scott A. Smith was appointed as Chief Executive Officer at Viatris Inc.
“On February 24, 2023, Viatris Inc. (the “Company”) appointed Scott A. Smith to serve as the Chief Executive Officer of the Company, effective as of April 1, 2023”
Scott Smith was appointed as Director at Viatris Inc.
“On December 29, 2022, the Board appointed Elisha Finney and Scott Smith to the Board, effective immediately.”
Elisha Finney was appointed as Director at Viatris Inc.
“On December 29, 2022, the Board appointed Elisha Finney and Scott Smith to the Board, effective immediately.”
Ian Read resigned as Director at Viatris Inc.
“On December 28, 2022, Class I directors Neil Dimick and Ian Read each notified Viatris Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”), effective immediately.”
Neil Dimick resigned as Director at Viatris Inc.
“On December 28, 2022, Class I directors Neil Dimick and Ian Read each notified Viatris Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”), effective immediately.”
Viatris Inc shareholders rejected Shareholder proposal regarding independent board chairman at the 2022-12-09 meeting.
“Proposal No. 4 – A shareholder proposal regarding independent board chairman: For Against Abstain Broker Non-Votes 386,308,608 454,640,169 3,660,905 154,375,659 This shareholder proposal was not approved.”
Viatris Inc shareholders approved Ratification of the selection of Deloitte & Touche LLP as independent auditor at the 2022-12-09 meeting.
“Proposal No. 3 – Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022: For Against Abstain Broker Non-Votes 942,960,216 54,046,575 1,978,551 N/A This proposal was approved.”
Viatris Inc shareholders approved Approval, on a non-binding advisory basis, of the 2021 compensation of the named executive officers at the 2022-12-09 meeting.
“Proposal No. 2 – Approval, on a non-binding advisory basis, of the 2021 compensation of the named executive officers of the Company: For Against Abstain Broker Non-Votes 763,132,088 78,356,451 3,121,393 154,375,410 This proposal was approved.”
Viatris Inc shareholders approved Election of four Class II directors at the 2022-12-09 meeting.
“Proposal No. 1 - Election of the following four Class II directors, each to hold office until the 2023 annual meeting of shareholders: Nominee For Against Abstain Broker Non-Votes W. Don Cornwell 830,712,236 12,537,152 1,360,557 154,375,396 Harry A. Korman 739,053,362 101,674,978 3,881,604 154,375,397 Rajiv Malik 795,235,812 48,085,750 1,288,389 154,375,391 Richard A. Mark, C.P.A. 802,917,647 40,404,867 1,287,429 154,375,399 Each Class II director was elected to hold office until the 2023 annual meeting of shareholders.”
Viatris Inc completed a disposition involving Biocon Biologics Limited for $3.335 billion on a cash-free, debt-free basis, consisting of (a) $2.0 billion in cash consideration at closing, subject to certain adjustments as set forth in (closed 2022-11-28).
“On November 29, 2022, Viatris Inc., a Delaware corporation (“ Viatris ”), announced that it closed the previously announced transaction with Biocon Biologics Limited, a public limited company incorporated under the India Companies Act, 2013 (“ Biocon Biologics ”), involving the transfer by Viatris of substantially all of its biosimilars portfolio (the “ Biosimilars Business ”) to Biocon Biologics and its subsidiaries (the “ Transaction ”) in exchange for consideration from Biocon Biologics and its subsidiaries of $3.335 billion on a cash-free, debt-free basis, consisting of (a) $2.0 billion in cash consideration at closing, subject to certain adjustments as set forth in the Transaction Agreement (as defined below), (b) a convertible preferred equity stake in Biocon Biologics initially representing 12.9% of the equity in Biocon Biologics (on a fully diluted basis), which the parties’ valued at $1 billion in the Transaction, (c) $160.0 million in future cash consideration, payable on the”
Viatris Inc amended Amendment No. 1 with Biocon Biologics Limited (effective 2022-11-28).
“On November 28, 2022, prior to the closing of the Transaction, Viatris and Biocon Biologics entered into Amendment No. 1 (" Amendment No. 1 ") to the Transaction Agreement, dated as of February 27, 2022, between Viatris and Biocon Biologics”
Viatris Inc reported the period ended September 30, 2022 results: revenue "$4.08 billion", net income "$354 million". Guidance reaffirmed.
“Adjusted EBITDA and Free Cash Flow; Driven by Solid Operating Momentum Despite Foreign Exchange Headwinds and Absorbing Inflation Impact to Date • Reports Total Revenues of $4.08 billion; U.S. GAAP Net Earnings of $354 million; Adjusted EBITDA of $1.50 billion; U.S. GAAP Net Cash Provided by Operating Activities of $869 million; and Free Cash Flow of $765 million”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.